Intervention
Retatrutide
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 17 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
17 shownA Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 · 2026-01-24
ACTIVE_NOT_RECRUITINGA Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 · 2025-11-17
ACTIVE_NOT_RECRUITINGA Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846 · 2025-06-06
COMPLETEDA Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859 · 2025-06-02
ACTIVE_NOT_RECRUITINGA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 · 2025-05-29
ACTIVE_NOT_RECRUITINGA Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 · 2025-03-05
ACTIVE_NOT_RECRUITINGA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 · 2024-11-01
ACTIVE_NOT_RECRUITINGThe Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 · 2024-04-30
ACTIVE_NOT_RECRUITINGEffect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 · 2024-04-10
COMPLETEDEffect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 · 2024-03-15
ACTIVE_NOT_RECRUITINGEffect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 · 2024-02-21
ACTIVE_NOT_RECRUITINGA Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 · 2023-08-01
COMPLETEDA Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 · 2023-07-20
COMPLETEDA Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · 2023-07-11
COMPLETEDA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · 2023-07-10
COMPLETEDA Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · 2023-05-30
COMPLETEDPre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401
AVAILABLECommon conditions
Obesity10Overweight6Type 2 Diabetes3Obstructive Sleep Apnea2Atherosclerotic Cardiovascular Disease (ASCVD)1Cardiovascular Diseases1Chronic Kidney Disease (CKD)1Chronic Low Back Pain (CLBP)1CKD1Diabetes Mellitus1Diabetes Mellitus, Type 21Diabetes Type 21Insulin Sensitivity1Obesity-related Complications1Osteo Arthritis Knee1Osteoarthritis, Knee1Overweight or Obesity1Type 2 Diabetes Mellitus1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING9
COMPLETED7
AVAILABLE1
Phase mix
PHASE313
PHASE12
PHASE21
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.